Ochsner Health System
ochsner.orgTotal trials
56
Active
6
Phase 3
2
Total enrollment
4,140
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Aspirin | — | — | — | — | — | 1 | |
| P2Y12 inhibitor | — | — | — | — | — | 1 |
Next readouts
- 2025-12-31
Top conditions
- Neuroendocrine Carcinoma2
- Emergence Delirium2
- Strabismus2
- Cirrhosis, Liver2
- Coronary Artery Disease2
- Anesthesia2
- Orthopedic Disorder2
- Dementia2
Frequently asked questions about Ochsner Health System
- How many clinical trials does Ochsner Health System have on ClinicalTrials.gov?
- Ochsner Health System is listed as the lead sponsor on 56 clinical trials in ClinicalTrials.gov, 6 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Ochsner Health System's trials are in Phase 3?
- 2 of Ochsner Health System's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Ochsner Health System focus on?
- Ochsner Health System's most-studied conditions on ClinicalTrials.gov are Neuroendocrine Carcinoma, Emergence Delirium, Strabismus, Cirrhosis, Liver, Coronary Artery Disease.
- When are Ochsner Health System's next clinical trial readouts?
- Ochsner Health System has 1 upcoming primary-completion readout tracked here; the soonest is “Colonoscopy and Antiplatelet Therapy Trial”, expected around 2025-12-31.